Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial

Advanced Ovarian Cancer Responds to Claudin-Targeted Drug in Preliminary Trial

Summary

Partial responses in half of patients with platinum-resistant disease, as crowded ADC list grows

Description

Partial responses in half of patients with platinum-resistant disease, as crowded ADC list grows

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source